Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer Reid, T., Fisher, G., Carter, C., Cho-Phan, C., Kunz, P., Oronsky, B., Fanger, G. R., Caroen, S., Parker, C., Scicinski, J. AMER ASSOC CANCER RESEARCH. 2015
View details for DOI 10.1158/1538-7445.AM2015-CT119
View details for Web of Science ID 000371597100016